Renalis, a Cleveland-based digital healthcare startup, has secured $824k in pre-seed funding to develop treatments of pelvic health disorders.
The round was led by the Healthcare Collaboration Fund, a fund managed through a partnership between JumpStart Inc and University Hospitals Ventures, counting with participation from several individual and private investors. Neil Wyant, Managing Director of UH Ventures, referred to the firm’s participation in the round by stating:
“Renalis has an opportunity to address very prevalent and debilitating pelvic health conditions. Our investment enables UH to be its ‘living laboratory’ so that we can prove out Renalis’ novel approach and have an even bigger impact on patient care.”
The startup aims to develop technology that enables patients to better record and manage the symptoms of conditions like Overactive Bladder (OAB). To achieve this, it developed its first digital therapeutic product as a mobile application by the name of “CeCE”.
The new funds will be destined to boost research efforts within healthcare systems, support regulatory efforts, and grow the startup’s team in a strategic manner to improve the commercialization of its technology. Renalis CEO, Missy Lavender, said about the use of the funds:
“We are so grateful for this latest funding round. We can now accelerate our go-to-market plan to deliver evidence-based solutions to chronic, expensive, and prevalent conditions like OAB to millions of patients in the U.S. and beyond.”
The digital healthcare startup has committed to the development of FDA-approved prescription digital therapeutics since being founded in 2018, looking to help the more than 33 million Americans who suffer from some form of pelvic health disorder.
Now, Renalis is focusing on the development of new solutions to assist patients experiencing stress incontinence, bowel dysfunction, chronic pelvic pain, menstrual disorders, and other conditions that affect the quality of life of millions around the globe.
Credit: Source link
Comments are closed.